Thyroscope develops a wearable device that analyzes thyroid risk levels using bio-signals from the body, providing real-time health updates without the need for blood tests. This technology addresses the challenge of monitoring thyroid health by offering a non-invasive and continuous assessment method.
Funding
$3.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Monitoring thyroid health traditionally requires frequent blood tests, which can be inconvenient, costly, and time-consuming for patients, especially those needing regular check-ups. Existing methods offer limited continuous data, hindering timely detection of thyroid abnormalities and personalized management of thyroid conditions.
Solution
Thyroscope is developing a suite of AI-powered solutions called Glandy that leverage wearable sensor data and image analysis to monitor thyroid health. Their initial products focus on thyroid eye disease (TED), using AI to analyze 2D and 3D images for activity scoring, protrusion measurement, and eyelid retraction monitoring. Future products aim to use smartwatch-collected heart rate data to monitor the risk of hyperthyroidism and hypothyroidism. The Glandy platform seeks to provide continuous, non-invasive thyroid monitoring, enabling earlier detection and more proactive management of thyroid disorders.
Target Audience
The primary target audience includes endocrinologists, ophthalmologists, and general practitioners involved in the diagnosis and management of thyroid disorders, as well as patients requiring regular thyroid monitoring.
Features
- **Glandy CAS:** AI-based 2D image analysis for assessing and monitoring thyroid eye disease activity.
- **Glandy EXO:** 3D deep-learning-based image analysis for measuring and monitoring eye protrusion.
- **Glandy LID:** AI-based 2D image analysis for monitoring eyelid retraction (planned for 2024).
- **Glandy HYPER:** Smartwatch-based heart rate analysis for monitoring hyperthyroidism risk (planned for 2025).
- **Glandy HYPO:** Smartwatch-based heart rate analysis for monitoring hypothyroidism risk (planned for 2025).
- **Glandy TDF:** Smartwatch-based heart rate analysis for monitoring general thyroid dysfunction risk (planned for 2025).